Effects of Combination Treatment on Renal Endothelial Function in Type 2 Diabetes Mellitus

Merve Günes-Altan1,2, Agnes Bosch1, Kristina Striepe1

  • 1Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.

PubMed
Abstract

Insights

Nitric oxide (NO) activity influences renal hemodynamics in type 2 diabetes mellitus (T2DM) patients treated with empagliflozin and linagliptin (E+L). This NO activity is a key factor in the renal hemodynamic response to E+L therapy.

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) is associated with altered renal hemodynamics.
  • Previous studies showed that combination therapy with empagliflozin and linagliptin (E+L) impacts renal hemodynamics in T2DM patients.

Purpose of the Study:

  • To investigate the role of nitric oxide (NO) activity in the renal vasculature on the hemodynamic changes induced by E+L combination therapy in T2DM patients.

Main Methods:

  • Randomized controlled trial comparing E+L with metformin and insulin glargine (M+I) in T2DM patients for 3 months.
  • Renal hemodynamics (renal plasma flow, glomerular filtration rate) assessed using clearance techniques.
  • Renal NO activity evaluated by measuring changes in renal plasma flow in response to an NO inhibitor (L-NMMA).

Main Results:

  • E+L treatment correlated significantly with changes in renal plasma flow (RPF), renal vascular resistance (RVR), and efferent arteriolar resistance (RE) related to NO activity.
  • No significant correlations between renal NO activity and hemodynamic changes were observed in the M+I group.
  • No overall change in renal NO activity was detected in either group.

Conclusions:

  • Renal NO activity is a determinant of the renal hemodynamic response to E+L combination therapy in T2DM.
  • The therapeutic effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors, like empagliflozin, may be partly mediated by influencing renal NO activity.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
858
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
581
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
209